脑肿瘤的分子分类指导个性化治疗

doi:10.3969/j.issn.1006-7795.2015.05.026

首都医科大学学报 ›› 2015, Vol. 36 ›› Issue (5): 794-799.doi: 10.3969/j.issn.1006-7795.2015.05.026

脑肿瘤的分子分类指导个性化治疗

高华¹, 赵鹏², 张亚卓¹

1. 北京市神经外科研究所细胞生物室中枢神经损伤修复北京市重点实验室首都医科大学, 北京 100050;
2. 首都医科大学附属北京天坛医院神经外科, 北京 100050

收稿日期:2015-07-14 出版日期:2015-10-21 发布日期:2015-10-20
基金资助:
国家自然科学基金(30971005, 81272522, 81072075)。

Molecular classification of brain tumors guides individualized treatment

Gao Hua¹, Zhao Peng², Zhang Yazhuo¹

1. Cell biology, Beijing Neurosurgical Institute, Capital Medical University, Key Laboratory of Central Nervous System Injury, Beijing 100050, China;
2. Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing 100050, China

Received:2015-07-14 Online:2015-10-21 Published:2015-10-20
Contact: 张亚卓 E-mail:zyz2004520@yeah.net
Supported by:
This study was supported by National Natural Science Foundation of China (30971005, 81272522, 81072075).

摘要/Abstract

摘要： 原发性脑肿瘤危害极大,很大程度上是因为对当前的治疗不敏感。目前对脑肿瘤的治疗日新月异,主要挑战为如何针对特定人群开展个体化治疗。综述近年来脑肿瘤方面的研究进展,建议对脑肿瘤的分子分类增加更多的生物学信息。基于肿瘤基因组和蛋白质组学技术产生出的大量信息和数据,将成为脑肿瘤分子分类和个性化治疗的基础。

关键词: 脑肿瘤, 分子分类, 个性化治疗

Abstract: Primary brain tumors are among the most lethal of all cancers, largely as a result of their lack of responsiveness to current therapy. Numerous new therapies hold great promise for the treatment of patients with brain cancer, but the main challenge is to determine which treatment is most likely to benefit an individual patient. By reviewing advances of brain tumors,we suggest that a more biological approach to brain tumors classification will provide improved means to type these tumors. Any new classification, however, must be based on clinical significance, and we thus point out the pressing need for better clinical endpoints and outcome measures in the field.

Key words: brain tumor, molecular classification, individualized treatment

中图分类号:

高华, 赵鹏, 张亚卓. 脑肿瘤的分子分类指导个性化治疗[J]. 首都医科大学学报, 2015, 36(5): 794-799.

Gao Hua, Zhao Peng, Zhang Yazhuo. Molecular classification of brain tumors guides individualized treatment[J]. Journal of Capital Medical University, 2015, 36(5): 794-799.

参考文献

[1] Legler J M, GloecklerRies L A, Smith M A, et al.RESPONSE: re: brain and other central nervous system cancers: recent trends in incidence and mortality [J]. J Natl Cancer Inst, 2000,92(1):77A-78A.
[2] Takeshima H, Sawamura Y, Gilbert M R, et al. Application of advances in molecular biology to the treatment of brain tumors[J].Curr Oncol Rep, 2000,2(5):425-433.
[3] Giannini C, Scheithauer B W, Weaver A L, et al. Oligodendrogliomas: reproducibility and prognostic value of histologic diagnosis and grading[J]. J Neuropathol Exp Neurol, 2001, 60(3):248-262.
[4] Hlaihel C,Boussel L, Cochet H, et al. Dose and image quality comparison between prospectively gated axial and retrospectively gated helical coronary CT angiography[J]. Br J Radiol, 2011, 84(997): 51-57.
[5] Louis D N, Ohgaki H, Wiestler O D, et al. The 2007 WHO classification of tumours of the central nervous system[J]. Acta Neuropathol, 2007, 114(2):97-109.
[6] Phillips H S, Kharbanda S, Chen R, et al. Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis[J]. Cancer Cell, 2006, 9(3):157-173.
[7] Nutt C L, Mani D R, Betensky R A, et al. Gene expression-based classification of malignant gliomas correlates better with survival than histological classification[J]. Cancer Res, 2003, 63(7):1602-1607.
[8] Hartmann C, Hentschel B, Tatagiba M, et al. Molecular markers in low-grade gliomas: predictive or prognostic?[J]. Clin Cancer Res, 2011, 17(13):4588-4599.
[9] Masui K, Cloughesy T F, Mischel P S. Molecular pathology in adult high-grade gliomas: from molecular diagnostics to target therapies[J]. Neuropathol Appl Neurobiol, 2012, 38(3):271-291.
[10] Weller M, Pfister S M, Wick W, et al. Molecular neuro-oncology in clinical practice: a new horizon[J]. Lancet Oncol, 2013, 14(9):e370-e379.
[11] Al-Hajj M, Becker M W, Wicha M, et al. Therapeutic implications of cancer stem cells[J]. Curr Opin Genet Dev, 2004, 14(1):43-47.
[12] Stiles C D, Rowitch D H. Glioma stem cells: a midterm exam[J]. Neuron, 2008, 58(6):832-846.
[13] Sukhdeo K, Hambardzumyan D, Rich J N. Glioma development: where did it all go wrong?[J]. Cell, 2011, 146(2):187-188.
[14] Trouillas J. In search of a prognostic classification of endocrine pituitary tumors[J]. Endocr Pathol, 2014, 25(2):124-132.
[15] Li Z B, Niu G, Wang H, et al. Imaging of urokinase-type plasminogen activator receptor expression using a Cu-64-labeled linear peptide antagonist by microPET[J]. Clin Cancer Res, 2008, 14(15):4758-4766.
[16] Arakaki P A, Marques M R, Santos M C. MMP-1 polymorphism and its relationship to pathological processes[J]. J Biosci, 2009, 34(2):313-320.
[17] Alta M, Bayrak O F, Ayan E, et al.The effect of polymorphisms in the promoter region of the MMP-1 gene on the occurrence and invasiveness of hypophyseal adenoma [J].Acta Neurochir (Wien). 2010;152(9):1611-1617.
[18] Hussaini I M, Trotter C, Zhao Y, et al. Matrix metalloproteinase-9 is differentially expressed in nonfunctioning invasive and noninvasive pituitary adenomas and increases invasion in human pituitary adenoma cell line[J]. Am J Pathol, 2007, 170(1):356-365.
[19] Mete O, Ezzat S, Asa S L. Biomarkers of aggressive pituitary adenomas[J]. J Mol Endocrinol, 2012, 49(2):R69-R78.
[20] Tong Y, Zheng Y, Zhou J, et al. Genomic characterization of human and rat prolactinomas[J]. Endocrinology, 2012, 153(8):3679-3691.
[21] Wang F, Gao H, Li C, et al. Low levels of PRB3 mRNA are associated with dopamine-agonist resistance and tumor recurrence in prolactinomas[J]. J Neurooncol, 2014, 116(1):83-88.
[22] David A, Hwa V, Metherell L A, et al. Evidence for a continuum of genetic, phenotypic, and biochemical abnormalities in children with growth hormone insensitivity[J]. Endocr Rev, 2011, 32(4):472-497.
[23] Zhan X, Desiderio D M. Signaling pathway networks mined from human pituitary adenoma proteomics data[J]. BMC Med Genomics, 2010, 3:13.
[24] Jiang Z, Gui S, Zhang Y. Analysis of differential gene expression using fiber-optic bead array and pathway analyses in pituitary adenomas[J]. J Clin Neurosci, 2011, 18(10):1386-1391.
[25] Ozfirat Z, Korbonits M. AIP gene and familial isolated pituitary adenomas[J]. Mol Cell Endocrinol, 2010, 326(1-2):71-79.

脑肿瘤的分子分类指导个性化治疗

Molecular classification of brain tumors guides individualized treatment

PDF

可视化

被引次数

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 4

编辑推荐

Metrics

本文评价

[1]	杨燕琳, 陈光强, 何璇, 史中华, 徐明, 周建新. 危重患者疼痛观察工具在颅脑肿瘤开颅术后疼痛评估中的应用[J]. 首都医科大学学报, 2019, 40(5): 758-763.
[2]	于春水;李坤成;秦文. 弥散张量纤维束成像在脑肿瘤手术的应用[J]. 首都医科大学学报, 2005, 26(4): 413-417.
[3]	齐慧敏. 颅脑疾患术后肾缺血引起尿中表皮生长因子变化的研究[J]. 首都医科大学学报, 1997, 18(3): 242-245.
[4]	田竞生;邓枫;田华;郑少鹏;徐群渊. 人脑肿瘤c-erb B基因扩增的研究[J]. 首都医科大学学报, 1993, 14(4): 247-249.